Premium
The Pharmacokinetics of Methadone Following Co‐Administration with a Lamivudine/Zidovudine Combination Tablet in Opiate‐Dependent Subjects
Author(s) -
Rainey Petrie M.,
Friedland Gerald H.,
Snidow Jerry W.,
McCanceKatz Elinore F.,
Mitchell Susan M.,
Andrews Laurie,
Lane Barbara,
Jatlow Peter
Publication year - 2002
Publication title -
the american journal on addictions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.997
H-Index - 76
eISSN - 1521-0391
pISSN - 1055-0496
DOI - 10.1080/10550490252801657
Subject(s) - pharmacokinetics , lamivudine , zidovudine , methadone , cmax , volume of distribution , pharmacology , opiate , medicine , oral administration , human immunodeficiency virus (hiv) , virology , viral disease , virus , hepatitis b virus , receptor
Methadone pharmacokinetics were determined in an open‐label, within subject study in 16 methadone‐maintained, non‐HIV‐infected subjects prior to and following administration of one lamivudine 150‐mg/zidovudine 300‐mgcombi‐nation tablet to determine whether this antiretroviral therapy alters methadone serum concentrations. No significant differences in the mean are aunder the serum concentration‐time curve (AUC 0‐2 4h; 8753 ± 4280 vs. 8641 ± 4431 μg‐h/L), oralclearance(CL/F;9.9± 4.9vs.10.3 ± 5.5 L/h), oral volume of distribution (Vd/F; 647 ± 465 vs. 481 ± 305 L), maximum serum concentration (C max ; 514 ± 223 vs. 5510 ± 237 μg/L), or terminal elimination half‐life (t l/2 ; 55.3 ± 61.0 vs. 35.0 ± 17.5 h) were detected. These results suggest that methadone dose change is not likely to be necessary for patients treated with lamivudine/zidovudine combination pharmacotherapy.